Cell and Gene Therapy, Industrial Impact

Characterization and identification of glucuronide metabolites

April 21, 2023

Characterization and identification
This technical note demonstrates the comprehensive characterization and confident identification of glucuronide metabolites from hepatocyte incubations of midazolam. An orthogonal fragmentation mechanism was applied to generate diagnostic fragmentions for confident identification of glucuronide metabolites

Spotlight

Be The Match BioTherapies

Be The Match BioTherapies® partners with cell and gene therapy companies to save lives through autologous and allogeneic cellular therapy.

OTHER WHITEPAPERS
news image

Microfluidics: Big developments on thesmall scale

whitePaper | February 23, 2023

Life sciences is a blanket term used to describe the study of all things relative to living organisms, such as biology, physiology, and biochemistry.

Read More
news image

Best Practices for RIM Business Process Automation

whitePaper | December 15, 2022

Regulatory teams at life science companies are finding that effective regulatory information management (RIM) has become critical to their operations.

Read More
news image

Leveraging innovations in plasmid manufacturing to bring advanced therapies to market

whitePaper | December 13, 2022

The global demand for plasmid DNA has increased dramatically in recent years, fueled by a surge in the clinical development of next-generation cell and gene therapy products and more recently by the success of COVID-19 vaccines.

Read More
news image

Document quality control emerges as a discipline in its own right

whitePaper | November 19, 2022

Compiling a quality regulatory submission is a basic requirement for biopharmaceutical companies. Poor quality documents could lead to rejection of a regulatory application,

Read More
news image

New Diagnostic Approaches for Undiagnosed Rare Genetic Diseases

whitePaper | April 16, 2020

Accurate diagnosis is the cornerstone of medicine; it is essential for informed care and promoting patient and family well-being. However, families with a rare genetic disease (RGD) often spend more than five years on a diagnostic odyssey of specialist visits and invasive testing that is lengthy, costly, and often futile, as 50% of patients do not receive a molecular diagnosis.

Read More
news image

U.S. NATIONAL SCIENCE FOUNDATION

whitePaper | August 21, 2022

The “Government Performance and Results Act” and the “GPRA Modernization Act of 2010 require federal agencies to develop strategic plans setting forth long-term goals and objectives. Guidance.

Read More

Spotlight

Be The Match BioTherapies

Be The Match BioTherapies® partners with cell and gene therapy companies to save lives through autologous and allogeneic cellular therapy.

Events